FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977753616> ?p ?o ?g. }

• W2977753616 endingPage "S680" @default.
• W2977753616 startingPage "S680" @default.
• W2977753616 abstract "Purpose: Anti-TNF-α therapy is effective for the treatment of inflammatory bowel disease (IBD). Nevertheless, over 30% of IBD patients fail to respond to anti-TNF-α therapy and approximately 60% of the patients who respond initially to the therapy will lose the response over time and will need to either dose escalation or switch to another agent to maintain response. Low serum drug levels and/or anti-drug antibody (ADA) generation may play a role for the failure and, recent data suggest monitoring of patients for serum drug and ADA levels is an important strategy for optimal patient management. Here, we report the application of the homogeneous mobility shift assay (HMSA) method for monitoring of adalimumab (ADL) and human antibodies-to-adalimumab (ATA) in serum samples from patients who lost response to ADL treatment. Methods: Serum samples were collected from 100 patients who initially responded to ADL therapy for at least three months but were beginning to lose response. ATA and ADL levels in the serum samples were measured by ATA- and ADL-HMSA as described previously, except that in the ATA-HMSA Alexa Fluor 488 labeled ADL (ADL-488) was used as antigen and rabbit anti-ADL serum as standard. Full analytical method validation of both the ATA- and the ADL-HMSA was performed, and cut points for ADL and ATA levels were established with 100 drug-naïve healthy controls. The relationship of the ADL drug level and ATA generation in these patients was analyzed. Results: Validation of the ATA- and ADL-HMSA revealed a lower limit of detection to be 0.026 μg/mL for ATA and 0.018 μg/mL for ADL in the serum samples. The intra-assay and inter-assay precision determination yielded a coefficient of variation of less than 15%, and the accuracy of the assay is within 20% for both assays. ADL drug tolerance in ATA HMSA is up to 40 μg/ml in the test serum. Serum samples from 100 drug-naïve healthy subjects were tested to set up the cutoff point of 0.55U/mL (Mean+3.0xSD) for ATA and 0.66 μg/mL for ADL. Analysis of 100 serum samples from patients who were losing response showed that 36% of the patients had an ADL level < 3 μg/mL, of these 58.3% were ATA positive. However, only 18% of the patients (4/22) had ATA when their ADL level was over 20 μg/mL. Overall, 40% of the patient (40/100) were positive for ATA. Conclusion: Analysis of ADL and ATA levels in non-responding IBD patients showed a high incidence of ATA generation and the ADL levels were inversely correlated with the level of ATA generation. Drug and ADA levels are important determinants of patient response to the therapy. Disclosure: Shui-Long Wang, Scott Hauenstein, Linda Ohrmund, Reshma Shringarpure, Jared Salbato, Rukmini Reddy, Kevin McCowen, Shawn Shah, Steven Lockton, Emil Chuang and Sharat Singh are employees of Prometheus Laboratories, Inc. Dr. Douglas Wolf and Dr. Isam Diab have no finance disclosure. This research was supported by an industry grant. The funding of the study was supported by Prometheus Laboratories, Inc." @default.
• W2977753616 created "2019-10-10" @default.
• W2977753616 creator A5002673377 @default.
• W2977753616 creator A5011843783 @default.
• W2977753616 creator A5013683501 @default.
• W2977753616 creator A5024034724 @default.
• W2977753616 creator A5032111173 @default.
• W2977753616 creator A5034576675 @default.
• W2977753616 creator A5037971056 @default.
• W2977753616 creator A5040561097 @default.
• W2977753616 creator A5065621943 @default.
• W2977753616 creator A5080135700 @default.
• W2977753616 creator A5082691959 @default.
• W2977753616 creator A5083660873 @default.
• W2977753616 creator A5091293213 @default.
• W2977753616 date "2012-10-01" @default.
• W2977753616 modified "2023-10-16" @default.
• W2977753616 title "Influence of Trough Serum Drug Level and Immunogenicity on the Lack of Response to Adalimumab Therapy in IBD Patients Presidential Poster" @default.
• W2977753616 doi "https://doi.org/10.14309/00000434-201210001-01680" @default.
• W2977753616 hasPublicationYear "2012" @default.
• W2977753616 type Work @default.
• W2977753616 sameAs 2977753616 @default.
• W2977753616 citedByCount "0" @default.
• W2977753616 crossrefType "journal-article" @default.
• W2977753616 hasAuthorship W2977753616A5002673377 @default.
• W2977753616 hasAuthorship W2977753616A5011843783 @default.
• W2977753616 hasAuthorship W2977753616A5013683501 @default.
• W2977753616 hasAuthorship W2977753616A5024034724 @default.
• W2977753616 hasAuthorship W2977753616A5032111173 @default.
• W2977753616 hasAuthorship W2977753616A5034576675 @default.
• W2977753616 hasAuthorship W2977753616A5037971056 @default.
• W2977753616 hasAuthorship W2977753616A5040561097 @default.
• W2977753616 hasAuthorship W2977753616A5065621943 @default.
• W2977753616 hasAuthorship W2977753616A5080135700 @default.
• W2977753616 hasAuthorship W2977753616A5082691959 @default.
• W2977753616 hasAuthorship W2977753616A5083660873 @default.
• W2977753616 hasAuthorship W2977753616A5091293213 @default.
• W2977753616 hasConcept C126322002 @default.
• W2977753616 hasConcept C159654299 @default.
• W2977753616 hasConcept C1862650 @default.
• W2977753616 hasConcept C203014093 @default.
• W2977753616 hasConcept C2779134260 @default.
• W2977753616 hasConcept C2780035454 @default.
• W2977753616 hasConcept C2780132546 @default.
• W2977753616 hasConcept C2780868878 @default.
• W2977753616 hasConcept C71924100 @default.
• W2977753616 hasConcept C79544238 @default.
• W2977753616 hasConcept C98274493 @default.
• W2977753616 hasConceptScore W2977753616C126322002 @default.
• W2977753616 hasConceptScore W2977753616C159654299 @default.
• W2977753616 hasConceptScore W2977753616C1862650 @default.
• W2977753616 hasConceptScore W2977753616C203014093 @default.
• W2977753616 hasConceptScore W2977753616C2779134260 @default.
• W2977753616 hasConceptScore W2977753616C2780035454 @default.
• W2977753616 hasConceptScore W2977753616C2780132546 @default.
• W2977753616 hasConceptScore W2977753616C2780868878 @default.
• W2977753616 hasConceptScore W2977753616C71924100 @default.
• W2977753616 hasConceptScore W2977753616C79544238 @default.
• W2977753616 hasConceptScore W2977753616C98274493 @default.
• W2977753616 hasLocation W29777536161 @default.
• W2977753616 hasOpenAccess W2977753616 @default.
• W2977753616 hasPrimaryLocation W29777536161 @default.
• W2977753616 hasRelatedWork W1972257299 @default.
• W2977753616 hasRelatedWork W2024148297 @default.
• W2977753616 hasRelatedWork W2056662730 @default.
• W2977753616 hasRelatedWork W2084986335 @default.
• W2977753616 hasRelatedWork W2146142445 @default.
• W2977753616 hasRelatedWork W2799707556 @default.
• W2977753616 hasRelatedWork W3009905127 @default.
• W2977753616 hasRelatedWork W3213047483 @default.
• W2977753616 hasRelatedWork W4242353256 @default.
• W2977753616 hasRelatedWork W4252031817 @default.
• W2977753616 hasVolume "107" @default.
• W2977753616 isParatext "false" @default.
• W2977753616 isRetracted "false" @default.
• W2977753616 magId "2977753616" @default.
• W2977753616 workType "article" @default.